Skip to content

Our
Science

Science with a Purpose

We conduct rigorous research and development in areas of serious unmet medical need, with a focus on antibody and fusion proteins, antibody-drug conjugates (ADCs), and bifunctional antibodies, to target treatments and attack disease. The potential of these therapies can be seen in our rich pipeline of innovative drugs with over 15 indications, with five of those indications currently in pivotal trials.
RC18
Antibody and Fusion Protein Platform
By taking the best pieces of different proteins to create new fusion antibodies, we can better target the immune system in autoimmune diseases.
More about antibody and fusion proteins
RC48
Antibody-Drug Conjugate (ADC) Platform
These molecular trios specifically deliver chemotherapies directly to tumor cells—all while sparing healthy cells.
More about ADCs
RC28
Bifunctional Antibody Platform
Two are better than one—these dual-acting antibodies can target multiple regulating molecules at once to slow disease progression.
More about bifunctional antibodies